15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $875M | $71M | 50.8% | 31.5% | $246M | $43M | $186M |
| 2024 | $480M | $52M | 40.9% | 27.2% | $21M | $37M | $41M |
| 2023 | $248M | -$46M | 14.0% | -12.8% | -$8M | $37M | $22M |
| 2022 | $219M | -$425M | 7.0% | -185.4% | $36M | $36M | $34M |
| 2021 | $332M | $133M | 54.1% | 51.4% | $137M | $79M | $36M |
| 2020 | $274M | $106M | 57.5% | 55.9% | $25M | $0 | $26931 |
| 2019 | $1M | -$7M | 39.2% | -504.8% | -$4M | $0 | $1M |
| 2018 | $1M | -$950129 | 62.9% | -61.5% | -$480049 | $299996 | $119267 |
| 2017 | $23166 | $582062 | -31.6% | -24574.5% | — | — | $9449 |
| 2016 | — | -$7M | — | — | — | — | $10522 |
| 2015 | — | $83809 | — | — | $46704 | — | $122291 |
| 2014 | — | -$684342 | — | — | $161228 | — | $126833 |
| 2013 | — | $250489 | — | — | — | — | $26870 |
| 2012 | — | -$2M | — | — | -$510630 | — | $104721 |
| 2011 | — | -$383393 | — | — | -$639745 | — | $224800 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $216M | $47M | 42.4% | 37.5% | $74M | $41M | $207M |
| Dec '25 | $152M | $12M | 30.4% | 20.4% | $69M | $43M | $186M |
| Sep '25 | $268M | $55M | 57.8% | 48.7% | $99M | $44M | $166M |
| Jun '25 | $244M | -$18M | 51.2% | 13.8% | $27M | $39M | $97M |
| Mar '25 | $212M | $21M | 55.9% | 38.1% | $51M | $35M | $85M |
| Dec '24 | $258M | $62M | 55.0% | 44.4% | -$341000 | $37M | $41M |
| Sep '24 | $79M | -$9M | 27.8% | 12.3% | $6M | $37M | $47M |
| Jun '24 | $76M | -$364000 | 29.7% | 7.0% | $13M | $37M | $41M |
| Mar '24 | $67M | -$364000 | 15.1% | 2.1% | $2M | $36M | $30M |
| Dec '23 | $70M | -$32M | 19.0% | -37.5% | — | $37M | $22M |
| Sep '23 | $63M | -$6M | 11.3% | -1.3% | — | $39M | $27M |
| Jun '23 | $59M | -$3M | 16.4% | -0.6% | -$3M | $42M | $33M |
| Mar '23 | $56M | -$5M | 8.6% | -7.9% | -$3M | $36M | $33M |
| Dec '22 | $54M | -$15M | 1.0% | -10.8% | $12M | $36M | $34M |
| Sep '22 | $28M | -$412M | -83.5% | -1509.7% | -$13M | $25M | $37M |
| Jun '22 | $58M | -$19M | 11.4% | -2.4% | $10M | $16M | $48M |
| Mar '22 | $79M | $21M | 45.3% | 37.0% | $27M | — | $13M |
| Dec '21 | $63M | -$22M | 30.7% | 24.5% | $35M | $79M | $36M |
| Sep '21 | $118M | $74M | 64.4% | 63.1% | $21M | — | $6M |
| Jun '21 | $63M | $30M | 46.4% | 43.9% | $82M | — | $5M |
How the market has priced NUTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Nutex Health Inc.'s revenue has grown 26.1% per year, and net income declined 7.8% per year. These are computed facts, not advice.
As of FY2025, Nutex Health Inc. reported $43M of total debt against $186M of cash; operating income covered interest expense 12×.
In FY2025, gross margin was 50.8%, operating margin 31.5%, and net margin 8.1%.
As of Jun '26, Nutex Health Inc. traded at a price-to-earnings ratio of about 14.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.